EverPoint Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

EverPoint Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-81,250	Closed	-$1.75M	–	533
2016 Q1	$1.75M	Hold	81,250	–	–	0.03%	348
2015 Q4	$2.48M	Buy	+81,250	New	+$2.38M	0.05%	361

Other funds holding MRNS

Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

EverPoint Asset Management's MRNS Position: Q2 2016 in Review

EverPoint Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2016, closing a stake of 81,250 shares — an estimated $1.75M sold.

EverPoint Asset Management first reported a position in MRNS in Q4 2015 and held it in 2 quarters. The position peaked at $2.48M in Q4 2015. 28 funds tracked by Wall St. Rank hold MRNS as of Q2 2016.

EverPoint Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2016 after selling out during the quarter.
EverPoint Asset Management sold 81,250 Marinus Pharmaceuticals, Inc shares in Q2 2016, an estimated $1.75M.
EverPoint Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2015 and held it in 2 quarters.
EverPoint Asset Management's Marinus Pharmaceuticals, Inc position peaked at $2.48M in Q4 2015.
28 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2016.

Based on EverPoint Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.